



Contact

Karen Ard, Senior Managing Director · Boustead Securities
 karen@boustead1828.com · 303-886-4449

Keith Moore, CEO & Managing Director · Boustead Securities
 keith@boustead1828.com · 949-295-1580


PetCure Oncology, LLC is one of the market leading veterinary cancer treatment providers in the US and is revolutionizing the way pet cancer is treated using proven technology from the human oncology field, stereotactic radiation (“SRS/SRT”). We believe SRS/SRT allows the Company’s board-certified veterinary radiation oncologists to precisely target tumors in pets using large doses of radiation delivered with sub-millimeter accuracy over a very short period of time. The result is potentially far fewer side-effects, tumor control and fewer anesthetic events for pets (reduced from 20 to 3 or fewer). This market opportunity coincides with the “humanization of pets” as pet related products and services are experiencing unprecedented year over year growth, a trend that is projected to continue. According to Fetchacure.org, over 12,000,000 pets are diagnosed with cancer every year, while a fraction of these pets have access to meaningful treatment options.

Founded in 2014 and funded in 2015, the Company has treated over 3,000 pets to date at PetCure facilities which are geographically dispersed across the US (New Jersey, Arizona, California, Wisconsin, Pennsylvania and Florida). Treatment data on all 3,000+ pets has been documented and this data will generally form the foundation of evidence- based research, the intent of which is to prove the efficacy of SRS/SRT as a world class treatment option. With new locations in the pipeline, the Company intends to expand operations to 25 high-value markets to allow greater access to pet owners who could benefit from SRS/SRT through PetCure Oncology’s radiation oncology specialists.

Current PetCure Locations



PetCure Patients Treated by Cancer Type (According to the Company as of March 31, 2019)



Offering Terms

Security Type	6% Convertible Promissory Notes	Public Offering
Maximum Conversion Price	\$1.75	
Offering Size	Min: \$3M (4.9%) Max: \$10M (16.3%)	Use of Proceeds
Maturity Date	December 31, 2022	

We intend to conduct a Reg A+ IPO in Q1 2020, at which time all notes will convert.

Working Capital, New Locations, Additional Executives, Debt Disposition, Marketing, Deferred Salaries & Out of Pocket Expenses, Deferred Management Fees, Legal and Third-Party Expenses

Disclosure

There is no guarantee that any specific objective will be achieved. Investments may be illiquid, highly speculative and there is risk of the total loss of your investment. This is not a solicitation or offer to buy or sell securities. Please see offering documents for further risks and disclosures. Map and chart are for illustrative purposes only.